Evaluation of the Safety, Tolerability and Pharmacokinetics of HY8931 in Healthy Adult Participants
Summary
The goal of this clinical trial is to learn the safety, tolerability and pharmacokinetics of single and multiple doses of HY8931 in healthy adult participants. The main questions it aims to answer are: * How is the safety and tolerability following administration of single and multiple doses of HY8931 in healthy adult participants? * What is the PK character of HY8931 following administration of single and multiple doses of HY8931 in healthy adult participants? Researchers will compare HY8931 to a placebo (a look-alike substance that contains no drug) to see if HY8931 is safe and well tolerated. Participants will take HY8931 or a placebo once or twice in single dose group or multiple dose group. And will be follow-up until Day 90.
Timeline
- Start
- 2026-01-14
- Primary completion
- 2026-09
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HY8931 | Unknown | 10 mg | Intravenous |
| Subject | HY8931 | Unknown | 30 mg | Intravenous |
| Subject | HY8931 | Unknown | 60 mg | Intravenous |
| Subject | HY8931 | Unknown | 120 mg | Intravenous |
| Subject | HY8931 | Unknown | 240 mg | Intravenous |
| Subject | HY8931 | Unknown | 360 mg | Intravenous |
Indications
No indication recorded.